期刊档案 · IMMUNOLOGY

Frontiers in Immunology

ISSN 1664-3224 · Frontiers Media S.A. · SWITZERLAND

Frontiers in Immunology 中科院 医学 2区(2025 年升级版),影响因子 6.95,完全开放获取,收取 APC,金额未公布,近 24 个月 292 篇文章投稿到接收中位 63 天,2025 年发文 7,028 篇,SCIE、Scopus 收录。

影响因子6.95LetPub 汇总的最新公布值
中科院分区医学 2区2025 年升级版大类 · 2026 新锐版 医学 2区
审稿周期63 天投稿到接收中位数 · 近 24 个月 292 篇文章 · PubMed
版面费收取 APC,金额未公布完全开放获取
录用比例—暂无反馈
年发文量7,028 篇2025 年 · OpenAlex 统计

研究范围

研究范围与定位

Frontiers in Immunology 由 Frontiers Media S.A. 出版,属中科院医学大类(2025 升级版2区)。按 OpenAlex 近年发文统计,该刊主要发表 Immune Cell Function and Interaction、T-cell and B-cell Immunology、Cancer Immunotherapy and Biomarkers 等主题的论文,这 3 个主题约占 30.3%,主导子领域为 Immunology。(根据 OpenAlex 主题统计与中科院分区数据生成)

Frontiers in Immunology is a multidisciplinary journal that publishes research across basic, translational, and clinical immunology. The journal aims to showcase advances and novel approaches to diagnosing and treating immune disorders in both animal and cellular models, as well as in humans. Indexed in MEDLINE, PubMed Central, Scopus and the SCIE Frontiers in Immunology is the official Journal of the International Union of Immunological Societies (IUIS). Led by Field Chief Editor Pietro Ghezzi (Emeritus Professor at Brighton and Sussex Medical School), Frontiers in Immunology welcomes contributions that investigate the basic mechanisms of immune system development and function, with a particular emphasis on describing the clinical and immunological phenotype of human immune disorders and defining their molecular basis. Topics include: advances in biological drugs immune system development and function molecular basis of human immune disorders novel approaches to diagnosis and treatment of immune disorders precision medicine for immunological disorders studies on animal and cellular models and in humans studies on systems immunology with relevant experimental validation. Frontiers in Immunology particularly welcomes news ideas and approaches which supports and advances the UN’s Sustainable Development Goal (SDGs), specifically SDG 3: good health and well-being. The research published in this journal could lead to the development of new treatments and therapies for various immunological disorders, thereby promoting well-being for all. Manuscripts that focus on clinical studies, medical treatments, or human diseases without a clear connection to immunology are not suitable for publication in this journal. Additionally, studies that use analytical molecular biology techniques without a clear immunological context or contribution to the field of immunology are also not within the scope of this journal. Manuscripts focusing solely on cost-effectiveness studies are also not considered for publication in this journal. Frontiers’ journals require that manuscripts primarily comprising computational studies of public data, must include appropriate validation. Please refer to the Frontiers Standards for research methodology policy, for more information. Manuscripts not adhering to these standards will not be considered. Frontiers in Immunology is dedicated to propelling advancements in the field of Immunology by providing unrestricted access to articles and dissemina

摘自期刊官网 Aims & Scope

研究方向(LetPub):IMMUNOLOGY

编委会国家分布:未见中国大陆编委;主要国家 美国 5、意大利 4、澳大利亚 2、新加坡 2、英国 1(共 18 位编委标注了国家) 编委会 ↗出版商官网 ·

主要研究主题 OpenAlex 近年发文统计,占比为近似值

  1. Immune Cell Function and InteractionImmunology and Microbiology13.3%
  2. T-cell and B-cell ImmunologyImmunology and Microbiology9%
  3. Cancer Immunotherapy and BiomarkersMedicine8%
  4. Immunotherapy and Immune ResponsesImmunology and Microbiology7.7%
  5. Immune cells in cancerImmunology and Microbiology6.8%
  6. Immune Response and InflammationImmunology and Microbiology4.8%
  7. CAR-T cell therapy researchMedicine4.6%
  8. Ferroptosis and cancer prognosisMedicine3.9%

分区与收录

学科分区与数据库收录

中科院期刊分区表

期刊分区表( 2025年3月升级版)医学 2 区
类别学科分区
大类医学2 区
小类免疫学IMMUNOLOGY2 区

Top 期刊:否综述期刊:否

《新锐期刊分区表》( 2026年3月发布)医学 2 区
类别学科分区
大类医学2 区
小类免疫学IMMUNOLOGY2 区

Top 期刊:是综述期刊:未标注

期刊分区表( 2023年12月旧的升级版)医学 2 区
类别学科分区
大类医学2 区
小类免疫学IMMUNOLOGY2 区

Top 期刊:否综述期刊:否

数据库收录

SCIEScopusDOAJLetPub

国际期刊预警名单:各版本均未列入LetPub

期刊官网自述收录

Web of ScienceMEDLINEPMCEmbase出版商官网

其他:EBSCO、ProQuest、Dimensions、CNKI、CLOCKSS、Crossref

期刊官网列出的收录清单,未与各数据库逐一核对;Web of Science 各子库以上方记录为准。

不同版本、大类与小类分别展示,不将不同评价口径合并为一个分区值;投稿与考核前请确认所在机构采用的版本。

指标

影响力指标与发文规模

影响力指标

影响因子
6.95LetPub ·
影响因子(出版商公布)
7出版商官网 ·
CiteScore 2026-06
11.3LetPub ·
CiteScore(出版商公布)
11.3出版商官网 ·
SJR 2026-06
1.96LetPub ·
SNIP 2026-06
1.43LetPub ·
h-index
84LetPub ·
h-index
360OpenAlex ·
i10-index
31,801OpenAlex ·
两年平均被引
5.53OpenAlex ·
自引率
7.1%LetPub ·
Gold OA 文章占比
99.9%LetPub ·

发文规模

年文章数
6,551LetPub ·

逐年发文量 OpenAlex 统计 · 累计 57,680 篇 · 当年数据不完整

年份发文量其中 OA被引
20267,8257,8254,765
20257,0287,02838,374
20245,5255,52569,530
20236,5026,502134,166
20228,2218,221228,131
20216,1296,129243,600

不同来源的统计口径与观测时间不同,页面保留各来源原值;“出版商公布”为期刊官网自述数据。

审稿与录用

审稿周期与录用情况

文章统计的审稿周期 PubMed 登记的稿件日期 · 至

63 天投稿到接收中位数 · P25–P75 44 天 – 90 天

接收到上线
中位数 17 天(292 篇)
投稿到上线
中位数 82 天
样本
292 篇有投稿与接收日期的文章(窗口内共 15,862 篇),最近一篇接收于

只统计最终被录用并发表的文章,不含被拒稿件的处理时间,因此通常长于出版商公布的"首次决定时间"。

其他来源

平均审稿速度(社区反馈)
14 WeeksLetPub ·
投稿到发表(期刊自报)
约 14 周DOAJ ·
评审方式
单盲同行评审DOAJ

社区反馈来自投稿者样本,置信度 0.5,不代表期刊承诺;“出版商公布”的时间节点定义以官网为准。

费用与开放获取

版面费与开放获取政策

完全开放获取DOAJ

所有文章开放获取,通常向作者收取文章处理费(APC)。

来源文章处理费费用减免许可证观测时间
DOAJCHF 3,150有CC BY
OpenAlexCHF 3,150——
LetPubUSD 3,295有—

费用以期刊官网为准;不同来源的观测时间可能不同,页面保留各来源原值,不做平均。

投稿要求

文章类型与投稿政策(官网)

官网政策摘录AI 使用、利益冲突、许可与版权、开放获取、同行评审
AI 使用 Use of AI to create written or visual content

Authors should not list a generative AI technology as a co-author or author of any submitted manuscript. Generative AI technologies cannot be held accountable for all aspects of a manuscript and consequently do not meet the criteria required for authorship. If the author of a submitted manuscript has used written or visual content produced by or edited using a generative AI technology, this use mu…

原文 ↗出版商官网 ·
利益冲突 Safeguards against financial conflicts of interest

Only leading researchers acting as Associate Editors, who are not part of Frontiers' staff, can make acceptance decisions based on reviews performed by external experts acting as Community Reviewers or Reviewers. None have a financial incentive to accept articles, i.e. they are not paid for their role as Associate Editor or community Reviewer, and any award scheme is not linked to acceptances of m…

原文 ↗出版商官网 ·
许可与版权 Open access and copyright

Figures, tables, and images are published under a Creative Commons CC-BY license; permission must be obtained for copyrighted material from other sources. 模型摘要

All Frontiers' articles from July 2012 onwards are published with open access under the Creative Commons CC-BY license (the current version is CC-BY, version 4.0). This means that the author(s) retains copyright, but the content is free to download, distribute, and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article. Upon submission, the author(s)…

原文 ↗出版商官网 ·
开放获取 Open access and copyright

Articles from July 2012 onwards are open access under CC-BY version 4.0; authors retain copyright. 模型摘要

All Frontiers' articles from July 2012 onwards are published with open access under the Creative Commons CC-BY license (the current version is CC-BY, version 4.0). This means that the author(s) retains copyright, but the content is free to download, distribute, and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article. Upon submission, the author(s)…

原文 ↗出版商官网 ·
同行评审 Peer review

CrossMark policy: readers can locate the current version of content; Frontiers maintains published content and alerts readers to changes. 模型摘要

Our rigorous, transparent peer review process combines expert review and constructive dialogue to strengthen your manuscript.

原文 ↗出版商官网 ·

摘录来自期刊官网页面,仅保留原文片段;“模型摘要”由 Workers AI 生成并经原文校验,以官网为准。

基本信息

出版信息与官方入口

出版商
Frontiers Media S.A.
出版国家或地区
SWITZERLAND
出版语言
English
ISSN
1664-3224
学会 / 主办单位
International Union of Immunological Societies
官方链接

常见问题

关于 Frontiers in Immunology 的常见问题

Frontiers in Immunology 是中科院几区期刊?

2025 年升级版分区表中,Frontiers in Immunology 为医学 2区,小类 免疫学 2 区。2026 年新锐版分区表中为医学 2区。不同版本与大小类分区不能混用。

Frontiers in Immunology 的影响因子是多少?

LetPub 汇总的最新公布影响因子为 6.95,CiteScore 为 11.3,h-index 为 360。

Frontiers in Immunology 的审稿周期多长?

按 2024年10月至2026年10月(近 24 个月)292 篇已发表文章登记的日期,投稿到接收的中位数为 63 天(四分位 44–90 天);投稿社区反馈的平均审稿速度为约 14 周。文章统计只含被录用的稿件,出版商数据口径以官网为准,社区反馈来自投稿者样本,均不代表期刊承诺。

Frontiers in Immunology 的编委会里有中国学者吗?

期刊官网编委会页面上标注了国家的 18 位编委中,没有中国大陆学者;人数最多的国家是 美国(5 位)、意大利(4 位)、澳大利亚(2 位)。统计按编委会页面列出的机构国家计,仅供参考。

Frontiers in Immunology 被哪些数据库收录?

据 LetPub 与 DOAJ 记录,Frontiers in Immunology 被 SCIE、Scopus、DOAJ 收录。期刊官网自述还被 Web of Science、MEDLINE、PMC、Embase 收录,该清单未与各数据库逐一核对。

Frontiers in Immunology 是开放获取期刊吗?版面费多少?

Frontiers in Immunology 为完全开放获取。收取 APC,金额未公布。

来源与更新

本页事实来自 LetPub、OpenAlex、出版商官网、DOAJ;每个数字旁标注来源与观测日期,冲突数据保留各来源原值。LetPub 原始详情页:查看 ↗(2026-08-24 归档)。最近更新:。